Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
Ken Inada,1 Sakiko Yamada,2 Hisashi Akiyoshi,2 Yoshitsugu Kojima,2 Shuichi Iwashita,3 Jun Ishigooka4 1Department of Psychiatry, Tokyo Women’s Medical University, Tokyo, Japan; 2Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan; 3Headquarters of Clinical Developme...
Guardado en:
Autores principales: | Inada K, Yamada S, Akiyoshi H, Kojima Y, Iwashita S, Ishigooka J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d9c1c0e729e14e67a99eabede201054b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi T, et al.
Publicado: (2018) -
Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose M, et al.
Publicado: (2021) -
Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
por: Ying Zhang, et al.
Publicado: (2021) -
Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017) -
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
por: Durgam S, et al.
Publicado: (2017)